Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was downgraded by stock analysts at Truist Financial from a “buy” rating to a “hold” rating in a report released on Monday, Briefing.com reports. They currently have a $225.00 price objective on the biopharmaceutical company’s stock. Truist Financial‘s price objective indicates a potential upside of 36.36% from the stock’s previous close.
ALNY has been the topic of several other research reports. Raymond James Financial lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and dropped their target price for the company from $420.00 to $315.00 in a research report on Friday. Oppenheimer lowered their price objective on Alnylam Pharmaceuticals from $350.00 to $320.00 and set an “outperform” rating on the stock in a report on Friday. Wall Street Zen lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Wells Fargo & Company reduced their target price on Alnylam Pharmaceuticals from $253.00 to $220.00 and set an “equal weight” rating for the company in a report on Friday. Finally, Sanford C. Bernstein downgraded Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $376.00 to $199.00 in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $313.86.
View Our Latest Analysis on ALNY
Alnylam Pharmaceuticals Stock Performance
Shares of ALNY stock opened at $165.00 on Monday. Alnylam Pharmaceuticals has a 1-year low of $163.30 and a 1-year high of $479.79. The company has a market cap of $22.10 billion, a price-to-earnings ratio of 8.57 and a beta of 0.43. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.48 and a quick ratio of 2.43. The stock has a 50 day simple moving average of $236.49 and a 200-day simple moving average of $286.19.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, topping the consensus estimate of $1.66 by $14.60. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The firm’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.90 EPS. On average, equities research analysts expect that Alnylam Pharmaceuticals will post 6.58 EPS for the current fiscal year.
Insider Activity at Alnylam Pharmaceuticals
In other news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by company insiders.
Institutional Trading of Alnylam Pharmaceuticals
Several large investors have recently bought and sold shares of the business. Chicago Partners Investment Group LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 124.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 2,186 shares of the biopharmaceutical company’s stock worth $490,000 after purchasing an additional 1,213 shares during the last quarter. Rakuten Investment Management Inc. grew its position in shares of Alnylam Pharmaceuticals by 13.0% in the third quarter. Rakuten Investment Management Inc. now owns 20,289 shares of the biopharmaceutical company’s stock valued at $5,155,000 after purchasing an additional 2,328 shares in the last quarter. Provenance Wealth Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $527,000. GraniteShares Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals by 12.7% in the third quarter. GraniteShares Advisors LLC now owns 1,825 shares of the biopharmaceutical company’s stock valued at $450,000 after purchasing an additional 205 shares during the last quarter. Finally, Traynor Capital Management Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 22.6% in the third quarter. Traynor Capital Management Inc. now owns 12,818 shares of the biopharmaceutical company’s stock valued at $3,163,000 after purchasing an additional 2,360 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.
Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.
See Also
- Five stocks we like better than Alnylam Pharmaceuticals
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
